You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Patent: 9,532,949

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,532,949
Title:Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
Abstract: In one embodiment, the invention provides a new design of nanocarrier compositions that release their therapeutic load specifically at intraperitoneal cancers\' site. These nanocarriers are administered intraperitoneally and comprise a plurality of porous nanoparticulates that (a) are loaded with one or more pharmaceutically-active agents alone or in combination with imaging agents thus providing a theranostic value and (b) that are encapsulated by and that support a lipid bilayer which is disrupted upon contact with a reactive oxygen species generated within the environment of the cancer. In other embodiments, the invention provides methods of treatment and pharmaceutical compositions comprising nanocarriers as described herein.
Inventor(s): Zeineldin; Reema (Shrewsbury, MA)
Assignee: STC.UNM (Albuquerque, NM)
Application Number:14/233,527
Patent Claims:see list of patent claims

Details for Patent 9,532,949

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial STC.UNM (Albuquerque, NM) 2031-07-19 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial STC.UNM (Albuquerque, NM) 2031-07-19 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.